Vibe Bio helps biotechs by funding & guiding high-potential drug programs through value inflection points. Our core is a community of scientists, patients, and partners that are dedicated to helping you find the promising treatments that patients deserve.
Biotech companies have promising technology and assets that could benefit patients. However, limited working capital, in many scenarios, inhibits the development of these programs to surpass their inflection points.
We can help you:
Limited resources force biotechs to focus on only a single program, halting progress on other, promising candidates.
Why should you be forced to put all your eggs in one basket?
The discovery process is unpredictable, frequently leaving companies in need of additional data to prove their concept.
Why should you have to stop working, when the data shows that you’re on the verge of a breakthrough?
Regulators like the FDA and VCs often require additional experiments to be done before allowing a program to progress, a grant to be issued, or new infusion of capital to occur. These requests are expensive and unplanned.
Why should you be derailed when the finish line is in sight?
We’ve developed a new approach to biotech investing, called Inflection Point Financing.